Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Wilms Tumor 1Sarcoma 1Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glutamic Acid × Other hematologic neoplasm × Clear all
NCT00369564 2021-08-11

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

University of South Florida

Phase 3 Completed
250 enrolled 10 charts
GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡